TempraMed Technologies Ltd.
0.52
CAD
-0.04
(-7.14%)
ISIN
CA88024B1022
CUSIP
88024B102
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Ron Ezra Nagar
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Toronto Canada
- Website
- tempramed.com
- Similar Companies
- Business
- TempraMed Technologies Ltd. is a medical technology company that develops, manufactures, and commercializes portable, maintenance-free thermal protection solutions and smart medical storage devices for temperature-sensitive injectable pharmaceuticals. Founded in 2015 and headquartered in Herzliya, Israel, with corporate operations in Vancouver, British Columbia, Canada, the company operates within the medical device and personal cold-chain healthcare sectors. TempraMed serves healthcare markets internationally across North America, Europe, the Middle East, and Asia-Pacific, targeting patients and healthcare providers managing chronic conditions requiring insulin, GLP-1 receptor agonists, epinephrine, biologic therapies, and other temperature-vulnerable medications. The company’s product portfolio is built upon patented thermal insulation and phase-change material technologies designed to protect injectable drugs from extreme heat and freezing without requiring refrigeration, batteries, charging, or water activation. TempraMed’s primary product offerings include: VIVI Cap, a reusable, temperature-shielding replacement cap engineered for major pre-filled and reusable insulin pens, equipped with built-in electronic temperature monitoring indicators; VIVI Epi, an insulated protective carrying shield designed for epinephrine auto-injectors used in emergency allergy treatment; VIVI Vial, a thermal protective case developed for multi-dose medication vials; VIVI 8 Plus and VIVI Go, multi-unit travel cases engineered to protect multiple injection pens, GLP-1 medications, and pre-filled syringes; and VIVI Sharps, a compact and portable needle disposal and protection accessory. Additionally, the company provides smart digital health integration, incorporating temperature-logging capabilities and mobile application compatibility to assist in chronic disease management and medication adherence. In recent developments, TempraMed completed a corporate restructuring and reverse takeover transaction to list its common shares publicly on the Canadian Securities Exchange under the ticker symbol VIVI. The company has expanded its commercial focus to address the rapidly growing market for GLP-1 weight-loss and diabetes therapeutics, introducing tailored thermal protection solutions compatible with pens such as semaglutide and tirzepatide. Over the past two years, TempraMed has established strategic commercial partnerships and expanded its distribution networks across the United States, Canada, and Europe, growing its presence in retail pharmacy chains, medical supply distributors, and direct-to-consumer digital channels. Furthermore, the company has advanced development on its next-generation connected device pipeline, integrating wireless data transmission and real-time cold-chain tracking to support remote patient monitoring and clinical compliance.